Company profile
Eli Lilly and Company
NYSE: LLY · Healthcare · Drug Manufacturers - General
#11 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
93AFH 96DQ 96GM 76SS 99
v0.1 · 65/100 weight · provisional
↑ market scale, listing tenure · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$72.2B
Rev growth YoY (TTM)
+47.4%
Net income (FY)
$20.6B
Employees
50,000
as of 2026-08-01
Market cap
$1.1T
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$65.2B$65.2B2025
Net income$20.6B$20.6B2025
Total assets$112.5B$112.5B2025
Equity$26.5B$26.5B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product94%
Collaboration and Other Revenue6%
By geography
UNITED STATES67%
Europe18%
Non-US9%
JAPAN3%
CHINA3%
The read
What is Eli Lilly and Company’s revenue?
Eli Lilly and Company booked $65.2B in FY2025 revenue, growing 45% year over year — faster than most Healthcare companies we track, at a 31.7% net margin.
Peers · Healthcare
Centene Corp.81B+Johnson & Johnson80B+HCA Healthcare, Inc.78B+Merck & Co., Inc.84B+Pfizer Inc.76B+AbbVie Inc.81B+Neighbors
Marion →Key facts
CEODavid A. Ricks
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersIndianapolis, IN
ExchangeNYSE: LLY
Employees50,000
IPO date1972-06-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.